Myung-Chul Kim

Dr. Myung-Chul Kim

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LWLEI WANG
LEI WANG
YXYufeng Xiao
Yufeng Xiao
YLYuewan Luo
Yuewan Luo
RMRohan P. Master
Rohan P. Master
JMJiao Mo
Jiao Mo
WZWeizhou Zhang
Weizhou Zhang
An effective cancer therapy requires killing cancer cells and targeting the tumor microenvironment (TME). Searching for molecules critical for multiple cell types in the TME, we identified NR4A1 as one such molecule that can maintain the immune suppressive TME. Here, we establish NR4A1 as a valid target for cancer immunotherapy and describe a first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 degrades NR4A1 within hours in vitro and exhibits long-lasting NR4A1 degradation in tumors with an excellent safety profile. NR-V04 inhibits and frequently eradicates established tumors. At the mechanistic level, NR-V04 induces the tumor-infiltrating (TI) B cells and effector memory CD8+ T (Tem) cells and reduces monocytic myeloid-derived suppressor cells (m-MDSC), all of which are known to be clinically relevant immune cell populations in human melanomas. Overall, NR-V04–mediated NR4A1 degradation holds promise for enhancing anticancer immune responses and offers a new avenue for treating various types of cancers such as melanoma.

23 September 2024 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
MKMyung-Chul Kim
Myung-Chul Kim
NBNicholas Borcherding
Nicholas Borcherding
WSWoo-Jin Song
Woo-Jin Song
RKRyan Kolb
Ryan Kolb
WZWeizhou Zhang
Weizhou Zhang
Introduction: Single-cell RNA sequencing (scRNA-seq) has become an essential tool for uncovering the complexities of various physiological and immunopathological conditions in veterinary medicine. However, there is currently limited information on immune-suppressive cancer subsets in canine breast cancers. In this study, we aimed to identify and characterize immune-suppressive subsets of triple-negative canine breast cancer (TNBC) by utilizing integrated scRNA-seq data from published datasets.Methods: Published scRNA-seq datasets, including data from six groups of 30 dogs, were subjected to integrated bioinformatic analysis.Results: Immune modulatory TNBC subsets were identified through functional enrichment analysis using immune-suppressive gene sets, including those associated with anti-inflammatory and M2-like macrophages. Key immune-suppressive signaling, such as viral infection, angiogenesis, and leukocyte chemotaxis, was found to play a role in enabling TNBC to evade immune surveillance. In addition, interactome analysis revealed significant interactions between distinct subsets of cancer cells and effector T cells, suggesting potential T-cell suppression.Discussion: The present study demonstrates a versatile and scalable approach to integrating and analyzing scRNA-seq data, which successfully identified immune-modulatory subsets of canine TNBC. It also revealed potential mechanisms through which TNBC promotes immune evasion in dogs. These findings are crucial for advancing the understanding of the immune pathogenesis of canine TNBC and may aid in the development of new immune-based therapeutic strategies.

31 August 2024 in Journal of Veterinary Clinics
Verified
Journal Article
Open access
PDF file
SJSiwon Jeong
Siwon Jeong
JYJiwoong Yoon
Jiwoong Yoon
WSWoo-Jin Song
Woo-Jin Song
JCJongtae Cheong
Jongtae Cheong
YYYoungMin Yun
YoungMin Yun
MKMyung-Chul Kim
Myung-Chul Kim
Siwon Jeong, Jiwoong Yoon, Woo-Jin Song, Jongtae Cheong, Young-min Yun, Gee Euhn Choi, Myung-Chul Kim. J Vet Clin 2024;41:215-22. https://doi.org/10.17555/jvc.2024.41.4.215

31 August 2024 in Journal of Veterinary Clinics
Verified
Journal Article
Open access
PDF file
YJYunhee Joung
Yunhee Joung
JYJiwoong Yoon
Jiwoong Yoon
DLDong Ju Lee
Dong Ju Lee
WSWoo-Jin Song
Woo-Jin Song
JCJongtae Cheong
Jongtae Cheong
MKMyung-Chul Kim
Myung-Chul Kim
Yunhee Joung, Jiwoong Yoon, Dong Ju Lee, Woo-Jin Song, Jongtae Cheong, Hyunjung Park, Young-min Yun, Gee Euhn Choi, Myung-Chul Kim. J Vet Clin 2024;41:207-14. https://doi.org/10.17555/jvc.2024.41.4.207


5 July 2023 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
SLSaeyoung Lee
Saeyoung Lee
WSWoo-Jin Song
Woo-Jin Song
JPJongjin Park
Jongjin Park
MKMinkun Kim
Minkun Kim
SCSangkyung Choen
Sangkyung Choen
YYYoungMin Yun
YoungMin Yun
An 8-year-old, castrated male Shih-tzu dog (Case 1) showing ataxia and gait disorder was referred for neurological examination and magnetic resonance imaging. Through comprehensive examinations, the patient was tentatively diagnosed with meningoencephalitis of unknown origin (MUO) and treatment with prednisolone and cytosine arabinoside was started. The symptoms were improving with immunosuppressive treatment. However, severe bacterial cystitis occurred and we could not avoid tapering off prednisolone. Then, neurological signs recurred. Therefore, we added crisdesalazine, which allowed us to reduce the daily dosage of immunosuppressants easily. In another case, a 4-year-old, spayed female Yorkshire terrier dog (Case 2) was referred to our hospital showing a head tilt, circling, and loss of the menace reflex. The patient was tentatively diagnosed with MUO and treatment with some immunosuppressants was attempted. The clinical symptoms improved, but the alleviation was inadequate. Thus, we added crisdesalazine. The neurological signs then markedly improved. Moreover, the drugs could be tapered off more easily than before. Crisdesalazine is a novel drug that has antioxidant and anti-inflammatory action in brain disease and is used particularly for dementia. In this paper, we tried an off-label use of this drug in canine MUO patients, and found that it had, in these two patients, additional therapeutic effects on the MUO.